The potential role for iron overload and fungal infection in liver transplantation

Liver Transplantation

Volumn 12, Issue 12, 2006, Pages 1731-1732

  Snydman, David R ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; IRON; IRON BINDING PROTEIN; IRON CHELATING AGENT; LACTOFERRIN; TRANSFERRIN;

BACTEREMIA; BLOOD TRANSFUSION; BLYMPHOCYTE; CANDIDA; CELL FUNCTION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; EDITORIAL; FUNGAL COLONIZATION; HUMAN; HYPOTHESIS; INFECTION RISK; INHIBITION KINETICS; IRON OVERLOAD; LIVER TRANSPLANTATION; MUCORMYCOSIS; MULTIVARIATE ANALYSIS; MYCOSIS; OBSERVATIONAL STUDY; PHAGOCYTE; PRIORITY JOURNAL; RISK FACTOR; TLYMPHOCYTE; UNIVARIATE ANALYSIS; VIRUS INHIBITION;

HUMANS; IRON; IRON OVERLOAD; LIVER; LIVER TRANSPLANTATION; MYCOSES;

EID: 33845507292     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20871     Document Type: Editorial

References (20)

1. Alexander J, Limaye AP, Ko CW, Bronner MP, Kowdley KV. Association of hepatic iron overload with invasive fungal infection in liver transplant recipients. Liver Transplantation 2006;12:1799-1804.
2. Collins LA, Samore MH, Roberts MS, Luzzati R, Jenkins RL, Lewis WD, Karchmer AW. Risk factors for invasive fungal infections complicating organ transplant recipients. J Infect Dis 1994;170:644-652.
3. George MJ, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN, Rubin RH. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am J Med 1997; 103:106-113.
4. Patel R, Portela D, Badley AD, Harmsen WS, Larson-Keller JJ, Ilstrup DM, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996;62:926-934.
5. Nieto-Rodriguez JA, Kusne S, Manez R, Irish W, Linden P, Magnone M, et al. Factors associated with the development of candidemia and candidemia-related death among live transplant recipients. Ann Surg 1996;223:70-76.
6. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, doubleblind, placebo-controlled trial. Ann Intern Med 1999;131: 729-737.
7. Altes A, Remacha AF, Sarda P, Sancho FJ, Sureda A, Martino R, et al. Frequent severe iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant 2004;34:505-509.
8. Maertens J, Demuynck H, Verbeken EK, Zachee P, Verhoef GE, Vandenberghe P, Boogaerts MA. Mucormycosis in allogeneic bone marrow transplant recipients: report of 5 cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999;24:307-312.
9. Boelaert JR. de Locht M, Van Cutsem J, Kerrels V, Cantinieaux B, Verdonck A, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993;91: 1979-1986.
10. Hershko CH. Iron and infection. In: Hallberg L, Asp GA, eds. Iron Nutrition in Health and Disease. New York, NY: John Libbey and Company; 1996:231-238.
11. Ang O, Gungor M, Aricioglu F, Inane D, Sagduyu H, Uysal V, Kucuker M. The effect of parenteral iron administration on the development of Staphylococcus aurcus-induced experimental pyelonephritis in rats. Int J Exp Pathol 1990;71:507-511.
12. Mazzoleni G, De Sa D, Gately J, Riddell RH. Yersinia enterocolitica infection with ileal perforation associated with iron overload and deferoxamine therapy. Dig Dis Sci 1991; 36:1154-1160.
13. Lustbader ED, Hann HW, Blumberg BS. Serum ferritin as a predictor of host response to hepatitis B virus infection. Science 1983;220:423-425.
14. Fujihara T, Hayashi K. Lactoferrin inhibits herpes simplex virus type-1 (HSV-1) infection to mouse cornea. Arch Virol 1995;140:1469-1472.
15. Harmsen MC, Swart PJ, De Bethune MP, Pauwels R, De Clercq E, The TH, Meijer DK. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 1995; 172:380-388.
16. Patruta SI, Horl WH. Iron and infection. Kidney Int Suppl 1999;55(suppl 2):S125-S130.
17. Brock JH, DeSouza M. Immunoregulating by iron binding proteins. Immunol Today 1986;7:30-31.
18. Barnewall RE, Rikihisa Y. Abroggation of gamma interfer-on-induced inhibition of Ehrlichia chaffenesis infection in human monocytes with iron transferring. Infect Immunol 1994;62:4804-4810.
19. Teehan GS, Bahdouch D, Ruthazer R, Balakrishnan VS, Snydman DR, Jaber BL. Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 2004;38:1090-1094.
20. Boelaert JR, van Landuyt HW, Valcke, YJ, Daneels RF, Schurgers ML, Matthys EG, Gordis BZ, Van Landuyt HW. Iron overload in hemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant 1990;5:130-134.